Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

Inclusion criteria: 1. Sub-optimally controlled Type 2 Diabetes Mellitus (T2DM) patients treated with insulin glargine for a minimum of 3 months: * Sub-optimal: HbA1c level \>7% and fasting blood glucose \<130mg/dL 2. Male or Female ≥18 years old 3. Body Mass Index (BMI) \<40 4. 10% ≥HbA1c ≥7% 5. If taking Oral anti-diabetics (OADs), must be on stable dose for at least 1 months 6. Patients willing to sign data release consent form Exclusion criteria: 1. Diabetes other than T2DM 2. Enrolled in other clinical trials 3. Previous treatment with an insulin other than insulin glargine 4. Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or with Di Peptidyl Peptidase 4 (DPP-IV) inhibitors 5. Pregnant or lactating women 6. Contraindicated to Lantus (insulin glargine) / Apidra (insulin glulisine) / Novomix 30 (insulin aspart) 7. Treatment with systemic corticoid steroids within the last 3 months prior to study enter 8. Treatment with any investigational product within the last 3 months prior to study entry The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.